Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunomodulatory, Transplant, and Autoimmune Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD2 ECD-Fc Fusion Protein / Mutant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Includes Ig-like V-type and C2-type domains (aa 25-209). | View CD2 Products |
| Gene Delivery | CD2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. Suitable for T-cell engineering and overexpression studies; preserves native membrane conformation. | View CD2 Products |
| Benchmark Ab | Anti-CD2 (Sequence of Siplizumab). Recombinant positive control for assay calibration. | View CD2 Products |
| Validator | CD2 siRNA Set. For knockdown verification and specificity controls. | View CD2 Products |
| Ortholog Panel | CD2 / CD58 Cynomolgus / Mouse Orthologs. For cross-species pharmacokinetic and toxicology studies. | View CD2 Products |
| Ligand / Related Target A | CD58 (LFA-3) ECD-Fc Protein. Natural counter-receptor for CD2; essential for receptor-ligand blocking and binding competition assays. | View CD58 Products |
| Related Target B | CD48 (BLAST-1). CD2 ligand in rodents; species-specific binding studies and surrogate model development. | View CD48 Products |
| Related Target C | CD3E. Synergistic T-cell signaling complex; crucial for bispecific engagement (e.g., CD2 x CD3). | View CD3E Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CD2-CD58 Heterophilic Interaction Quantification | Bidirectional SPR-validated ECD-Fc constructs with theoretical MW confirmation; native disulfide bond formation in HEK293 system. |
| Cross-species Preclinical Translation (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence identity verified by mass spectrometry. |
| T-cell Activation Modulation (Co-stimulatory Blockade) | Cell-based Lentivirus system for stable Jurkat/CD2 reporter lines; preserves native membrane orientation. |
| Specificity Control vs. SLAM Family | CD48 protein available for off-target binding assessment; high-resolution differentiation from CD2. |
| Glycosylation-dependent Epitope Recognition | HEK293-expressed (native glycosylation) ensuring physiological folding and epitope presentation. |
| Lack of Controls | Clinical Benchmark Antibodies (biosimilars, e.g., Siplizumab) included for assay validation. |
| False Positives in Flow Cytometry | Validated siRNA set included for specificity checks and knockdown confirmation. |
Live CD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Mechanism Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The CD2 therapeutic landscape is experiencing renewed interest, evolving from first-generation broad immunosuppression toward targeted T-cell adhesion disruption and selective depletion. First-generation approaches (Alefacept, LFA-3-Ig fusion) established proof-of-concept for psoriasis and transplant indications. Current R&D focuses on next-generation modalities including bispecific constructs that modulate CD2-CD58 interactions without complete systemic immune suppression, and Fc-engineered antibodies for fine-tuned depletion (e.g., Siplizumab for GVHD and organ transplantation). The shift toward precision immunology, transplant rejection management, and T-cell malignancies creates demand for reagents that can distinguish between partial agonism, antagonism, and complete blockade. Modern pipelines also explore CAR-T enhancement strategies and bispecific T-cell engagers (e.g., CD2 x CD3) for hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist/Depleting) | Biogen (Historical), ITB Med, BioTransplant | Autoimmune Diseases, GVHD, Organ Transplant | Epitope binning, ADCC validation (Need high-purity ECD-Fc and Benchmark Ab) |
| Fusion Protein (LFA-3-Ig) | AbbVie (Alefacept), Astellas / Biogen (Historical) | Plaque Psoriasis, Autoimmune | Receptor blocking assays (Need CD58 ligand proteins) |
| Bispecific (CD2 x CD58) | Emerging Biotechs, Academic Consortia | Psoriasis, Transplant Rejection | Heterophilic binding disruption (Need CD2-Fc + CD58-Fc pair) |
| Bispecific T-cell Engager (CD2 x CD3) | Early Stage Biotech | T-cell Malignancies | Heterodimer validation (Need cross-reactive antibodies and CD3E reagents) |
| CAR-T Enhancement | Cell Therapy Developers | Hematological Malignancies | Cell surface expression validation (Need Lentivirus for stable T-line) |
Key Mutations and Genetic Variants
CD2 exhibits several natural variants that may influence antibody epitope recognition and functional assays. Key mutations annotated in UniProt (P06729) include:
- rs1652154638: A somatic mutation identified in a breast cancer sample (VAR_035504).
- rs699738: A population variant (VAR_017104) located within the extracellular domain.
- rs35880225: Another variant (VAR_033608) present in the coding region.
These variants are important for epitope binning and cross-reactivity studies; TarMart CD2 ECD-Fc proteins are wild-type but can be adapted for mutational analysis.
Related Targets Network
CD2 sits within the immunological synapse signaling network. Key cross-sell targets include:
- CD58 (LFA-3): Primary ligand in humans; essential for functional blockade assays.
- CD48 (BLAST-1, SLAMF2): Ligand in rodents; required for species-specific validation.
- CD3E: T-cell co-receptor for bispecific engagements.
- CD28: Co-stimulatory checkpoint often evaluated in combination with CD2 pathway blockade.